Related Experiment Video
Updated: Sep 19, 2025
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
Published on: September 28, 2018
Structure-based discovery and conformational analysis of non-phosphomimetic bidentate inhibitor for protein tyrosine
Sanghwa Yoon1, Juyoung Cho1, Jisu Kim2
1Division of Bio & Medical Bigdata Department (Brain Korea 21 Four), Gyeongsang National University, Jinju 52828, Republic of Korea.
Abstract:
Protein tyrosine phosphatase 1B (PTP1B) is a key regulator of glucose homeostasis and signaling pathways, making it an attractive therapeutic target for type 2 diabetes, obesity, and cancer. However, conventional phosphomimetic inhibitors suffer from poor bioavailability and selectivity due to the flat, positively charged, and solvent-exposed nature of the PTP1B active site. To address these limitations, we employed a structure-based molecular modeling approach-combining high-throughput virtual screening, molecular dynamics, UMAP analysis, and JS divergence-to investigate novel non-phosphomimetic bidentate inhibitors. Among the identified candidates, COM68 and COM63 exhibited stable binding modes with favorable binding free energies. However, UMAP-based structural quantification revealed that COM63 displayed higher residue fluctuations at key binding sites, particularly R24 and F182. Subsequent in vitro assays confirmed that COM63 was inactive at the tested concentrations, suggesting that these excess fluctuations hindered effective PTP1B inhibition. In contrast, COM68 demonstrated an IC50 of 72 μM, indicating its potential as a lead compound for further optimization. Furthermore, ADMET predictions of COM68 indicated favorable pharmacokinetic properties, supporting its suitability for future drug development. This study identified a novel non-phosphomimetic bidentate inhibitor and highlighted the importance of stabilizing interactions at key residues in PTP1B inhibitor design. These findings provide structural insights for developing more selective and effective PTP1B inhibitors.
Insights
Researchers identified a novel non-phosphomimetic inhibitor, COM68, for Protein Tyrosine Phosphatase 1B (PTP1B), a target for diabetes and obesity. COM68 shows potential for drug development due to favorable properties and effective inhibition.
Area of Science:
- Biochemistry
- Pharmacology
- Computational Chemistry
Background:
- Protein tyrosine phosphatase 1B (PTP1B) is a crucial regulator of glucose metabolism and cellular signaling.
- PTP1B is a therapeutic target for type 2 diabetes, obesity, and cancer.
- Existing phosphomimetic inhibitors face challenges with bioavailability and selectivity due to the PTP1B active site's characteristics.
Purpose of the Study:
- To identify novel non-phosphomimetic bidentate inhibitors for PTP1B using a structure-based molecular modeling approach.
- To overcome the limitations of conventional PTP1B inhibitors.
- To provide structural insights for designing improved PTP1B inhibitors.
Main Methods:
- Structure-based molecular modeling, including high-throughput virtual screening, molecular dynamics, UMAP analysis, and JS divergence.
- Identification and evaluation of novel non-phosphomimetic bidentate inhibitor candidates.
- In vitro assays and ADMET predictions to assess inhibitor efficacy and pharmacokinetic properties.
Main Results:
- COM68 and COM63 were identified as potential bidentate inhibitors with favorable binding.
- COM63 showed instability at key binding sites (R24, F182) and lacked inhibitory activity.
- COM68 exhibited an IC50 of 72 μM and favorable ADMET predictions, indicating its potential as a lead compound.
Conclusions:
- COM68 represents a promising non-phosphomimetic bidentate inhibitor for PTP1B.
- Stabilizing interactions at key residues is critical for effective PTP1B inhibitor design.
- This study offers valuable structural insights for developing more selective and potent PTP1B inhibitors for metabolic diseases and cancer.
Related Concept Videos
02:54Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include: